Role of Innate Immune Dysregulation in the Etiology of Dementia
先天免疫失调在痴呆病因学中的作用
基本信息
- 批准号:10618888
- 负责人:
- 金额:$ 110.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdoptedAgonistAlzheimer&aposs DiseaseAnti-Bacterial AgentsB-LymphocytesBindingBrainButyratesCellsCholecalciferolChronicClinical TrialsCognitionComplexDementiaDiseaseEconomicsEpithelial CellsEpitheliumEtiologyExerciseFundingHealthHerpesviridaeHerpesviridae InfectionsHost DefenseHumanImmuneInfectionInfection preventionKnockout MiceKnowledgeLifeMacrophageMicrogliaMusNatural ImmunityNatural Killer CellsNatural regenerationNerve DegenerationNeuronsOralPeptidesPharmaceutical PreparationsPorphyromonas gingivalisPrevalenceProcessProductionProteomeRXRResearch PersonnelRiskRoleStructureTestingUnited States National Institutes of HealthUp-RegulationVaccinesViralVirulence Factorsantimicrobialbrain tissuecathelicidincathelicidin antimicrobial peptidecytotoxicityimprovedin vivoinsightneutrophilnovelnovel therapeuticspathogenpathogenic bacteriapathogenic viruspreventsymptom managementwound
项目摘要
Project Summary/Abstract
Increasing prevalence of Alzheimer’s dementia (AD) is a growing health and economic crisis. Although
studied for 112+ years, the root causes for sporadic AD—which is > 95% of AD—are unclear. Over the
last 15 years, 415+ clinical trials to test new drugs against AD failed. Approved drugs can only manage
symptoms. I will use NIH Pioneer funding to investigate a novel hypothesis for the etiology of sporadic
Alzheimer’s dementia, based on my insight that imbalance between two innate immune peptides may
be a key factor that modulates the risk of formation, the stability, and clearance of AD-associated fibrils
and plaques. Recent observations of chronic P. gingivalis and Herpesvirus infections being associated
with Alzheimer’s fit this hypothesis. I am, to my knowledge, the only researcher working on this idea.
The human cathelicidin LL-37, unique in our proteome, is an antiviral and antibacterial defense peptide
deployed by microglia, macrophages, neutrophils, epithelia, B cells, and NK cells (to kill infected cells).
Thus LL-37 is a centrally important defense peptide, necessary for killing bacterial and viral pathogens
and infected host cells. LL-37’s Vitamin D3-, RXR-agonist-, and butyrate-dependent expression is also
stimulated by infection, wounding, exercise, and some vaccines (e.g., BCG & OPV vaccines). Certain
pathogens, P. gingivalis in particular, release enzymatic virulence factors that rapidly degrade LL-37.
Degradation of LL-37 could well dysregulate the brain’s innate immunity, causing neurodegeneration;
in LL-37’s absence, the immune process of macroautophagy is crippled. The Alzheimer’s-associated
peptide Ab now seems also to be a host defense peptide; brain infections by either Herpesviridae or P.
gingivalis stimulate Ab production, causing it to accumulate in plaques that co-locate with pathogens.
Recently I and collaborators showed that LL-37 and Ab are both expressed in human brain, and bind
each other sequence-specifically. LL-37/Ab binding prevents fibrillization and blocks Ab from adopting
b-type secondary structure. Thus, LL-37 degradation may allow Ab to accumulate. Our in vivo studies
show that cathelicidin induction in 5XFAD mice slows AD progression and improves 5XFAD cognition
to match wild-type. I aim to tie this finding to infection-associated dementia. In this Pioneer project, I
will use wild-type and cathelicidin KO mice to demonstrate that degradation of LL-37 by P. gingivalis
virulence factors may well be one cause of brain tissue degradation leading to dementia, which can be
prevented by early upregulation of cathelicidin to prevent infection; or treated orally with antimicrobials.
My lab has developed new antimicrobials that potently kill both P. gingivalis and inactivate Herpesvirus.
项目摘要/摘要
阿尔茨海默氏症(AD)的发病率越来越高,是一种日益严重的健康和经济危机。虽然
经过112多年的研究,散发性阿尔茨海默病的根本原因--95%的阿尔茨海默病--尚不清楚。超过了
在过去的15年里,415多项测试AD新药的临床试验失败了。批准的药物只能管理
症状。我将使用NIH先驱基金来调查一种关于散发性疾病病因的新假说
阿尔茨海默氏症,基于我的洞察力,两种天然免疫肽之间的不平衡可能
是调节AD相关纤维的形成风险、稳定性和清除的关键因素
还有斑块。慢性牙龈假单胞菌与疱疹病毒感染相关的近期观察
阿尔茨海默氏症符合这个假设。据我所知,我是唯一一个致力于这一想法的研究人员。
人类盲肠毒素LL-37是一种抗病毒和抗细菌的防御肽,在我们的蛋白质组中是独有的。
由小胶质细胞、巨噬细胞、中性粒细胞、上皮细胞、B细胞和NK细胞部署(以杀死受感染的细胞)。
因此,LL-37是一种中枢重要的防御肽,是杀死细菌和病毒病原体所必需的
和被感染的宿主细胞。LL-37‘S维生素D3、RXR激动剂和丁酸依赖的表达
受感染、受伤、运动和一些疫苗(如卡介苗和口服脊髓灰质炎疫苗)的刺激。一定的
病原体,特别是牙龈假单胞菌,会释放酶毒性因子,迅速降解LL-37。
IL-37的降解可以很好地失调大脑的先天免疫,导致神经变性;
在LL-37‘S缺失的情况下,巨噬细胞自噬的免疫过程受阻。与阿尔茨海默病相关的
多肽抗体现在似乎也是一种宿主防御肽;疱疹病毒科或P。
牙龈杆菌刺激抗体的产生,使其在与病原体共存的菌斑中积累。
最近,我和他的合作者发现,IL-37和抗体都在人脑中表达,并与
彼此的序列--特别是。IL-37/Ab结合可阻止纤化并阻断Ab采用
B型二级结构。因此,LL-37的降解可能会使抗体积累。我们的活体研究
在5XFAD小鼠中诱导长春花碱可减缓AD进展并改善5XFAD认知
以匹配野生型。我的目标是将这一发现与感染相关的痴呆症联系起来。在这个先锋项目中,我
将使用野生型和盲肠毒素KO小鼠来证明牙龈假单胞菌对LL-37的降解
毒力因子很可能是导致痴呆的脑组织退化的原因之一,这可能是
通过早期上调长春瑞定以防止感染来预防;或口服抗菌素治疗。
我的实验室已经开发出新的抗菌剂,可以有效地杀死牙龈假单胞菌和灭活疱疹病毒。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.
- DOI:10.2147/ndt.s264910
- 发表时间:2021
- 期刊:
- 影响因子:3.2
- 作者:Fulop T;Tripathi S;Rodrigues S;Desroches M;Bunt T;Eiser A;Bernier F;Beauregard PB;Barron AE;Khalil A;Plotka A;Hirokawa K;Larbi A;Bocti C;Laurent B;Frost EH;Witkowski JM
- 通讯作者:Witkowski JM
Hyperactivation of monocytes and macrophages in MCI patients contributes to the progression of Alzheimer's disease.
- DOI:10.1186/s12979-021-00236-x
- 发表时间:2021-06-21
- 期刊:
- 影响因子:0
- 作者:Munawara U;Catanzaro M;Xu W;Tan C;Hirokawa K;Bosco N;Dumoulin D;Khalil A;Larbi A;Lévesque S;Ramassamy C;Barron AE;Cunnane S;Beauregard PB;Bellenger JP;Rodrigues S;Desroches M;Witkowski JM;Laurent B;Frost EH;Fulop T
- 通讯作者:Fulop T
Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.
- DOI:10.3390/ph14040304
- 发表时间:2021-03-31
- 期刊:
- 影响因子:0
- 作者:Diamond G;Molchanova N;Herlan C;Fortkort JA;Lin JS;Figgins E;Bopp N;Ryan LK;Chung D;Adcock RS;Sherman M;Barron AE
- 通讯作者:Barron AE
The anti-inflammatory effects of photobiomodulation are mediated by cytokines: Evidence from a mouse model of inflammation.
- DOI:10.3389/fnins.2023.1150156
- 发表时间:2023
- 期刊:
- 影响因子:4.3
- 作者:Shamloo, Shirin;Defensor, Erwin;Ciari, Peter;Ogawa, Gaku;Vidano, Laura;Lin, Jennifer S.;Fortkort, John A.;Shamloo, Mehrdad;Barron, Annelise E.
- 通讯作者:Barron, Annelise E.
Real-Time Monitoring of Multitarget Antimicrobial Mechanisms of Peptoids Using Label-Free Imaging with Optical Diffraction Tomography.
- DOI:10.1002/advs.202302483
- 发表时间:2023-08
- 期刊:
- 影响因子:15.1
- 作者:Kim, Minsang;Cheon, Yeongmi;Shin, Dongmin;Choi, Jieun;Nielsen, Josefine Eilso;Jeong, Myeong Seon;Nam, Ho Yeon;Kim, Sung-Hak;Lund, Reidar;Jenssen, Havard;Barron, Annelise E.;Lee, Seongsoo;Seo, Jiwon
- 通讯作者:Seo, Jiwon
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Annelise Emily Barron其他文献
Annelise Emily Barron的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Annelise Emily Barron', 18)}}的其他基金
Synthetic Antimicrobial Peptoids for Treatment of Chronic Suppurative Otitis Media
用于治疗慢性化脓性中耳炎的合成抗菌肽
- 批准号:
10384258 - 财政年份:2021
- 资助金额:
$ 110.48万 - 项目类别:
Role of Innate Immune Dysregulation in the Etiology of Dementia
先天免疫失调在痴呆病因学中的作用
- 批准号:
10437903 - 财政年份:2020
- 资助金额:
$ 110.48万 - 项目类别:
Role of Innate Immune Dysregulation in the Etiology of Dementia
先天免疫失调在痴呆病因学中的作用
- 批准号:
10263930 - 财政年份:2020
- 资助金额:
$ 110.48万 - 项目类别:
A Universal Front End to Improve Assembly Outcomes for Next-Gen Sequencing and Re
通用前端可改善下一代测序和重新组装的结果
- 批准号:
7853052 - 财政年份:2009
- 资助金额:
$ 110.48万 - 项目类别:
A Universal Front End to Improve Assembly Outcomes for Next-Gen Sequencing and Re
通用前端可改善下一代测序和重新组装的结果
- 批准号:
7945357 - 财政年份:2009
- 资助金额:
$ 110.48万 - 项目类别:
Calvarial Regeneration using Biomatrix-Encapsulated Skeletal Progenitors
使用生物基质封装的骨骼祖细胞进行颅骨再生
- 批准号:
7855466 - 财政年份:2009
- 资助金额:
$ 110.48万 - 项目类别:
Calvarial Regeneration using Biomatrix-Encapsulated Skeletal Progenitors
使用生物基质封装的骨骼祖细胞进行颅骨再生
- 批准号:
7936866 - 财政年份:2009
- 资助金额:
$ 110.48万 - 项目类别:
Ampetoids as Biostable Functional Mimics of Antimicrobial Peptides
Ampetoids 作为抗菌肽的生物稳定功能模拟物
- 批准号:
7572890 - 财政年份:2007
- 资助金额:
$ 110.48万 - 项目类别:
Fast Mutation Detection by Tandem SSCP/HA on Microchips
通过微芯片上的串联 SSCP/HA 进行快速突变检测
- 批准号:
7485498 - 财政年份:2007
- 资助金额:
$ 110.48万 - 项目类别:
Ampetoids as Biostable Functional Mimics of Antimicrobial Peptides
Ampetoids 作为抗菌肽的生物稳定功能模拟物
- 批准号:
7383060 - 财政年份:2007
- 资助金额:
$ 110.48万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 110.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 110.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 110.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




